Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics

To determine the difference in group 2 innate lymphoid cells (ILC2s) between healthy and severe allergic and eosinophilic asthma (SA) participants. Furthermore, to compare the effects of mepolizumab and omalizumab on SA following treatment
Conclusion:
ILC2s from severe allergic and eosinophilic asthma demonstrated an active phenotype typified by increased proliferation, TSLPR, GATA3 and NFATc1 expression and increased IL-5, IL-13 and IL-6 release. Mepolizumab reduced markers of ILC2s activation.